Crinetics Pharmaceuticals (NASDAQ:CRNX) vs. KalVista Pharmaceuticals (NASDAQ:KALV) Financial Survey

Crinetics Pharmaceuticals (NASDAQ:CRNX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Risk and Volatility

Crinetics Pharmaceuticals has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500.

Institutional and Insider Ownership

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Crinetics Pharmaceuticals and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	N/A	-32.28%	-29.45%
KalVista Pharmaceuticals	N/A	-195.62%	-89.96%

Valuation and Earnings

This table compares Crinetics Pharmaceuticals and KalVista Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$1.04 million	3,998.12	-$298.41 million	($4.11)	-10.74
KalVista Pharmaceuticals	$1.43 million	423.03	-$183.44 million	($3.94)	-3.03

KalVista Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Crinetics Pharmaceuticals and KalVista Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1	2	11	0	2.71
KalVista Pharmaceuticals	1	0	8	1	2.90

Crinetics Pharmaceuticals currently has a consensus price target of $74.45, suggesting a potential upside of 68.64%. KalVista Pharmaceuticals has a consensus price target of $26.43, suggesting a potential upside of 121.34%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.